PRImus‐AD study: Design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer’s disease (AD) with the orally available PRI‐002
The PRIMUS-AD phase 2 study will finally enroll about 300 patients with MCI and mild dementia due to AD to assess safety and therapeutic benefit of PRI-002. Results are expected mid-2026.
Authors
- Katja Lindner
- Dagmar Jürgens
- Knut Adermann
- Gunther Kauselmann
- Gerhard Tischler
- Alexander Brener
- Dieter Willbold
- Tina Bartsch
- Kathrin Zeiger
- Julie‐Anne Gabelich
- Oliver Peters
Institutions
- Forschungszentrum Jülich (DE)
- Ministerium für Verkehr des Landes Nordrhein-Westfalen (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103102
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00